Germline IgM predicts T cell immunity to Pneumocystis.
Adaptive immunity
Fungal infections
Immunology
Infectious disease
Proteomics
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
08 09 2022
08 09 2022
Historique:
received:
28
04
2022
accepted:
28
07
2022
pubmed:
3
8
2022
medline:
11
9
2022
entrez:
2
8
2022
Statut:
epublish
Résumé
Pneumocystis is the most common fungal pulmonary infection in children under the age of 5 years. In children with primary immunodeficiency, Pneumocystis often presents at 3-6 months of age, a time period that coincides with the nadir of maternal IgG and when IgM is the dominant Ig isotype. Because B cells are the dominant antigen-presenting cells for Pneumocystis, we hypothesized the presence of fungal-specific IgMs in humans and mice and that these IgM specificities would predict T cell antigens. We detected fungal-specific IgMs in human and mouse sera and utilized immunoprecipitation to determine whether any antigens were similar across donors. We then assessed T cell responses to these antigens and found anti-Pneumocystis IgM in WT mice, Aicda-/- mice, and in human cord blood. Immunoprecipitation of Pneumocystis murina with human cord blood identified shared antigens among these donors. Using class II MHC binding prediction, we designed peptides with these antigens and identified robust peptide-specific lung T cell responses after P. murina infection. After mice were immunized with 2 of the antigens, adoptive transfer of vaccine-elicited CD4+ T cells showed effector activity, suggesting that these antigens contain protective Pneumocystis epitopes. These data support the notion that germline-encoded IgM B cell receptors are critical in antigen presentation and T cell priming in early Pneumocystis infection.
Identifiants
pubmed: 35917185
pii: 161450
doi: 10.1172/jci.insight.161450
pmc: PMC9536272
doi:
pii:
Substances chimiques
Immunoglobulin M
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI120033
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL139930
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Références
Immunity. 2018 Oct 16;49(4):695-708.e4
pubmed: 30291027
mSphere. 2019 Sep 4;4(5):
pubmed: 31484742
Curr Opin Pediatr. 2020 Dec;32(6):780-789
pubmed: 33009121
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Infect Immun. 1991 Nov;59(11):3859-62
pubmed: 1682252
J Immunol. 2015 Jul 15;195(2):611-20
pubmed: 26041535
J Immunol Methods. 2016 May;432:72-81
pubmed: 26891811
Infect Immun. 2015 May;83(5):2043-52
pubmed: 25733518
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Fungi (Basel). 2021 Nov 18;7(11):
pubmed: 34829266
Sci Immunol. 2021 Sep 10;6(63):eabf1198
pubmed: 34516780
J Immunol. 2006 May 15;176(10):6147-54
pubmed: 16670323
Biochemistry. 2022 Aug 2;61(15):1585-1599
pubmed: 35834502
J Immunol. 2003 Aug 1;171(3):1423-30
pubmed: 12874234
Infect Immun. 2019 Jun 20;87(7):
pubmed: 31010812
Infect Immun. 2014 Jun;82(6):2417-23
pubmed: 24686066
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925696
J Exp Med. 2010 Dec 20;207(13):2907-19
pubmed: 21149550
Clin Infect Dis. 2013 Jan;56(2):171-9
pubmed: 23074306
Clin Infect Dis. 2001 Mar 15;32(6):855-61
pubmed: 11247708